Skip to main content
OpenTrials
Completed

NCT Number: NCT05936632

Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

London School of Economics

London, WC2A 2AE, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals previously or currently diagnosed with any type of cancer.
  • Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion criteria

  • Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).

Treatment and study plan

Discrete Choice Experiment (DCE)

Other

DCE survey experiment

Primary outcomes

  1. Preferences for treatment attributes and trade-offs between attributes.

    Time frame: Through study completion, an average of 4-8 weeks.

    Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).

Sponsors and collaborators

Lead sponsor

London School of Economics and Political Science

Other

Registry information

Official study title

Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 10, 2023
Registry last updated
Jun 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.